Epstein Secrets

nce the Parties' relative likelihood of success in establishing liability and damages against the immediate benefits derived from a settlement. See Prudential, 148 F.3d at 319. The Court weighs these factors against the best and worst possible outcomes for Plaintiffs. In re Cendant Corp. Litig., 264 F.3d

to trial. A district court retains the authority to decertify or modify a class at any time during the litigation if it proves to be unmanageable." Warfarin Sodium, 391 F.3d at 537 (citing Prudential, 148 F.3d at 321). Because of this, the "specter of decertification makes settlement an appealing alternative."

ssible recovery and reasonableness in light of the risks the parties would face if the case went to trial." Warfarin Sodium, 391 F.3d at 538 (citing Prudential, 148 F.3d at 322). The Court determines "whether the settlement represents a good value for a weak case or a poor value for a strong case." Id. In

to pay any more than what . . . class members are entitled to under the theories of liability that existed at the time the settlement was reached." Warfarin Sodium, 391 F.3d. at 538. Here, as Plaintiffs state, "Defendants operate a successful, well-known, multi-national automobile business." ECF No. 28. Even i

ssible recovery and reasonableness in light of the risks the parties would face if the case went to trial." Warfarin Sodium, 391 F.3d at 538 (citing Prudential, 148 F.3d at 322). The Court determines "whether the settlement represents a good value for a weak case or a poor value for a strong case." Id. In

to pay any more than what . . . class members are entitled to under the theories of liability that existed at the time the settlement was reached." Warfarin Sodium, 391 F.3d. at 538. Here, as Plaintiffs state, "Defendants operate a successful, well-known, multi-national automobile business." ECF No. 28. Even i

nce the Parties' relative likelihood of success in establishing liability and damages against the immediate benefits derived from a settlement. See Prudential, 148 F.3d at 319. The Court weighs these factors against the best and worst possible outcomes for Plaintiffs. In re Cendant Corp. Litig., 264 F.3d

to trial. A district court retains the authority to decertify or modify a class at any time during the litigation if it proves to be unmanageable." Warfarin Sodium, 391 F.3d at 537 (citing Prudential, 148 F.3d at 321). Because of this, the "specter of decertification makes settlement an appealing alternative."

ns for attorneys' [125] fees. In re Prudential Ins. Co. Am. Sales Prac. Litig. Agent Actions ("Prudential"), 148 F.3d 283, 323 (3d Cir. 1998). The "Prudential considerations are just that, prudential." In re Baby Products Antitrust Litig. ("Baby Products), 708 F.3d 163, 174 (3d Cir. 2013). Finally, the Th

ire "additional discovery, extensive pretrial motions addressing complex factual and legal questions, and ultimately a complicated, lengthy trial." Warfarin Sodium, 391 F.3d at 536. The action here, which has been pending for over three years, would require the analysis of records from "hundreds of consumers,"

ssible recovery and reasonableness in light of the risks the parties would face if the case went to trial." Warfarin Sodium, 391 F.3d at 538 (citing Prudential, 148 F.3d at 322). The Court determines "whether the settlement represents a good value for a weak case or a poor value for a strong case." Id. In

to pay any more than what . . . class members are entitled to under the theories of liability that existed at the time the settlement was reached." Warfarin Sodium, 391 F.3d. at 538. Here, as Plaintiffs state, "Defendants operate a successful, well-known, multi-national automobile business." ECF No. 28. Even i